144 related articles for article (PubMed ID: 6681533)
21. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
23. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
24. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II).
Dumas M; d'Athis P; de Gislain C; Escousse A; Guerrin J; Autissier N
Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):430-3. PubMed ID: 4044076
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
[TBL] [Abstract][Full Text] [Related]
26. [Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
Civalleri D; Esposito M; De Cian F; Balletto N; Vannozzi MO; Mondini G; Carrabetta S; Bocchio MM
G Chir; 1997 Apr; 18(4):175-81. PubMed ID: 9303630
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.
Sinkule JA; Hutson P; Hayes FA; Etcubanas E; Evans W
Cancer Res; 1984 Jul; 44(7):3109-13. PubMed ID: 6539169
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.
Russo A; Gianni L; Kinsella TJ; Klecker RW; Jenkins J; Rowland J; Glatstein E; Mitchell JB; Collins J; Myers C
Cancer Res; 1984 Apr; 44(4):1702-5. PubMed ID: 6704976
[TBL] [Abstract][Full Text] [Related]
30. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
32. The influence of intraarterial high-dose cisplatin with concomitant irradiation on arterial microanastomosis: an experimental study.
Wang ZH; Zhang SZ; Zhang ZY; Zhang CP; Hu HS; Kirwan J; Mendenhall WM
Am J Clin Oncol; 2009 Apr; 32(2):158-62. PubMed ID: 19307956
[TBL] [Abstract][Full Text] [Related]
33. Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat.
Choudhury R; Epemolu RO; Rai BL; Hider RC; Singh S
Drug Metab Dispos; 1997 Mar; 25(3):332-9. PubMed ID: 9172951
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.
Lu K; Yap HY; Loo TL
Cancer Res; 1983 Mar; 43(3):1405-8. PubMed ID: 6825110
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of vincristine sulfate in adult cancer patients.
Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.
Munck JN; Riggi M; Rougier P; Chabot GG; Ramirez LH; Zhao Z; Bognel C; Ardouin P; Herait P; Gouyette A
Cancer Res; 1993 Apr; 53(7):1550-4. PubMed ID: 8453622
[TBL] [Abstract][Full Text] [Related]
38. A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors.
Glode LM; Pitman SW; Ensminger WD; Rosowsky A; Papathanasopoulos N; Frei E
Cancer Res; 1979 Sep; 39(9):3707-14. PubMed ID: 383286
[TBL] [Abstract][Full Text] [Related]
39. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
40. [Superselective intra-arterial infusion chemotherapy of high-dose cisplatin for advanced paranasal sinus carcinomas].
Yokoyama J; Shiga K; Saijo S; Matumoto K; Ogawa Y
Gan To Kagaku Ryoho; 1999 Jun; 26(7):967-73. PubMed ID: 10396325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
